Article
Oncology
Paolo A. Ascierto, Anna M. Di Giacomo, Vanna Chiarion Sileni, Paola Queirolo, Francesco Spagnolo, Federica De Galitiis, Francesco Cognetti, Mario Mandala, Massimo Guidoboni, Gaetana Rinaldi, Roberta Depenni, Francesca Consoli, Teresa Troiani, Michele Guida, Riccardo Marconcini, Pier F. Ferrucci, Sabino Strippoli, Paolo Fava, Barbara Merelli, Ester Simeone, Lorenza Di Guardo, Diana Giannarelli, Massimo Maio, Pietro Quaglino, Michele Del Vecchio
Summary: The CheckMate 238 study demonstrated the benefits of nivolumab over ipilimumab for melanoma patients and showed a tolerable safety profile. The Italian Expanded Access Programme enrolled 611 patients with resected melanoma and showed similar clinical activity and safety of nivolumab in a real-life setting.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Se Ryeong Jang, Nikita Nikita, Joshua Banks, Scott W. Keith, Jennifer M. Johnson, Melissa Wilson, Grace Lu-Yao
Summary: This study examined the effectiveness of cancer immunotherapy in male and female patients with advanced melanoma and found that women may not benefit as much from combination ICIs as men would. Tumor mutation burden or estrogen level may serve as important biomarkers associated with ICI response in metastatic melanoma.
Article
Oncology
Toulsie Ramtohul, Axel Cohen, Manuel Rodrigues, Sophie Piperno-Neumann, Luc Cabel, Nathalie Cassoux, Livia Lumbroso-Le Rouic, Denis Malaise, Sophie Gardrat, Gaelle Pierron, Pascale Mariani, Vincent Servois
Summary: This study found that TGR(3m) is an important indicator for predicting the survival of patients with liver metastatic uveal melanoma, while the RECIST-based response assessment is no longer significant in the overall survival analysis. Immunotherapy regimens were associated with higher overall survival in the low TGR(3m) subgroup. TGR(0), disease-free interval, and the sum of target lesions at baseline were predictive factors for low TGR(3m), which can help in making treatment decisions for first-line immunotherapy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Sarah Bouchereau, Louise Chaplain, Magali Fort, Alain Beauchet, Thomas Sidibe, Marie Chapalain, Leire Gonzalez-Lara, Christine Longvert, Astrid Blom, Philippe Saiag, Elisa Funck-Brentano
Summary: Despite its low efficacy, chemotherapy with dacarbazine may have increased efficacy in melanoma patients previously treated with immune checkpoint inhibitors (ICI). The study aimed to evaluate the efficacy of dacarbazine in a controlled-group study of patients pre-treated or not with ICI. Results showed that dacarbazine offered a short-lived benefit in patients with progressive advanced disease despite ICI (+/- targeted therapy).
BRITISH JOURNAL OF CANCER
(2021)
Article
Medicine, Research & Experimental
Bettina Sobottka, Marta Nowak, Anja Laura Frei, Martina Haberecker, Samuel Merki, Mitchell P. Levesque, Reinhard Dummer, Holger Moch, Viktor Hendrik Koelzer
Summary: CD8+ tumor-infiltrating T cells play a crucial role in predicting responses to immune checkpoint inhibitors in immune-oncology. A computational diagnostic algorithm was established to quantitatively measure the spatial densities of these cells in tumor compartments, leading to the successful classification into immune diagnostic categories. This approach allows for efficient immune phenotyping of metastatic lesions, even in the absence of material from the invasive margin, providing valuable insights for immunotherapy strategies in metastatic melanoma.
LABORATORY INVESTIGATION
(2021)
Article
Oncology
Meredith S. Pelster, Stephen K. Gruschkus, Roland Bassett, Dan S. Gombos, Michael Shephard, Liberty Posada, Maura S. Glover, Rinata Simien, Adi Diab, Patrick Hwu, Brett W. Carter, Sapna P. Patel
Summary: The combination regimen of nivolumab plus ipilimumab shows activity in metastatic uveal melanoma, yielding deep and sustained confirmed responses.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Dermatology
Hannah-Lou Schilling, James A. Hutchinson, Sebastian Haferkamp
Summary: The introduction of clinical antibodies against PD-1 and CTLA-4 has greatly impacted cancer treatment, but immune-related adverse events remain a challenge. A recent study revealed that a subset of melanoma patients treated with PD-1 and CTLA-4 blockade is prone to develop hepatitis, and this risk is associated with the expansion of effector memory CD4+ T cells in blood before treatment. This finding highlights the potential of using T-EM cell expansion as a biomarker for identifying patients who may need prophylactic treatment against CMV.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2022)
Article
Biochemistry & Molecular Biology
Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Miroslawa Puskulluoglu, Joanna Lompart, Manuela Las-Jankowska, Katarzyna Krawczak, Ewa Wrona, Lech Zareba, Justyna Zubrowska, Jerzy Walocha, Stanislawa Bazan-Socha, Marek Ziobro
Summary: This study assessed the efficacy of Nivolumab and ipilimumab combination therapy in advanced melanoma patients in Poland. The results showed that the real-life effectiveness of the therapy was lower than in pivotal trials, but early responders were likely to continue the treatment. The occurrence of adverse events may serve as a predictor of clinical effectiveness.
Article
Oncology
Julia Lai-Kwon, Sarah Jacques, Matteo Carlino, Naima Benannoune, Caroline Robert, Clara Allayous, Barouyr Baroudjian, Celeste Lebbe, Lisa Zimmer, Zeynep Eroglu, Turkan Ozturk Topcu, Florentia Dimitriou, Andrew Haydon, Serigne N. Lo, Alexander M. Menzies, Georgina Long
Summary: This study investigates the efficacy of a combination therapy strategy involving low-dose ipilimumab (IPI) and an anti-PD1 antibody in advanced melanoma. The results show that the majority of patients who progress following low-dose IPI and subsequently receive IPI 3 mg/kg (IPI3) have a positive response to this treatment. This suggests that the dosage of IPI is critical for certain patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Amit Maity, Rosemarie Mick, Ramesh Rengan, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Daniel A. Pryma, Dana M. Patsch, Alisha P. Maity, Andy J. Minn, Robert H. Vonderheide, John N. Lukens
Summary: This study reports the final full clinical analysis of a phase I trial of radiation with ipilimumab in patients with melanoma. Radiotherapy followed by ipilimumab was well tolerated and yielded a response rate that compares favorably to ipilimumab alone. The recommended dose for subsequent phase 2 trials was 8 Gy x 3 doses, based on these results.
Article
Multidisciplinary Sciences
Andrew Patterson, Noam Auslander
Summary: This study identifies key mutated processes associated with immune checkpoint inhibitor response in melanoma patients, demonstrating improved predictive capability compared to tumor mutational burden.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel C. Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L. Currie, Wei Lin, Mary A. Tagliaferri, Jonathan Zalevsky, Mario Sznol, Michael E. Hurwitz
Summary: This study found that the combination of BEMPEG and NIVO showed promising antitumor activity in first-line metastatic melanoma, including extended median progression-free survival. Early on-treatment blood biomarkers were associated with treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Chao Cai, Ismaeel Yunusa, Ahmad Tarhini
Summary: The triplet treatment with atezolizumab, vemurafenib, and cobimetinib showed significant improvement in progression-free survival compared to the doublet regimen of vemurafenib and cobimetinib, but it was not cost-effective at the current threshold. Scenario analyses suggested that it could be cost-effective at longer time horizons with certain treatment strategies.
Review
Oncology
Lucia Vazquez-Montero, Maria del Carmen Alamo de la Gala, Luis de la Cruz-Merino
Summary: The development of immune checkpoint inhibitors has transformed the treatment of advanced melanoma. Nivolumab plus ipilimumab, along with other immunotherapy options, has shown efficacy for advanced melanoma. However, the combination therapy is associated with severe immune-related toxicity. This article reviews the efficacy and safety of nivolumab plus ipilimumab in advanced melanoma and explores the potential benefits for different patient subgroups.
FRONTIERS IN ONCOLOGY
(2023)
Review
Dermatology
Francesca Aroldi, Mark R. Middleton
Summary: Advances in the understanding of melanoma biology and immunology have led to the development of immune checkpoint inhibitors, which have shown impressive long-lasting responses in the treatment of melanoma. However, the toxicity of these drugs remains a significant concern.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Oncology
Anand Sharma, Amish Lakhani, Subhadip Ghosh-Ray, Salma Alam, Anwar Padhani, Andrew Gogbashian, Paul Nathan
Summary: This study aims to evaluate the incidence of small bowel lipomatosis in patients with aRCC on treatment with pazopanib and compare it with other TKIs. The findings show that small bowel lipomatosis is only seen in patients receiving pazopanib and it has no relation with treatment response.
ANTICANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, Gagan Bhatnagar, David J. Pinato, Christian Ottensmeier, Fabio Gomes, Giuseppe Luigi Banna
Summary: GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10-20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased peripheral neutrophil recruitment and PD-L1 expression on neutrophils with GCSF use and greater tumour volume decrease with higher tumour GCSF expression. However, its potential to increase neutrophil counts and, thus, NLR values, could subsequently confer poorer prognoses on patients with advanced NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Laura A. Ridgley, Jonathan Caron, Angus Dalgleish, Mark Bodman-Smith
Summary: The expression of activatory and inhibitory receptors on V gamma 9V delta 2 T-cells was assessed to explore the potential regulation of their activity. The results showed that V gamma 9V delta 2 T-cells expressed high levels of activatory markers and variable levels of inhibitory receptors, which were upregulated upon stimulation. However, immune checkpoint blockade had no effect on the cytotoxic capacity or cytokine production of V delta 2+ T-cells when cultured with tumor cells expressing cognate ligands.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Oncology
Mary Y. Wu, Scott T. C. Shepherd, Annika Fendler, Edward J. Carr, Lewis Au, Ruth Harvey, Giulia Dowgier, Agnieszka Hobbs, Lou S. Herman, Martina Ragno, Lorin Adams, Andreas M. Schmitt, Zayd Tippu, Benjamin Shum, Sheima Farag, Aljosja Rogiers, Nicola O'Reilly, Philip Bawumia, Callie Smith, Eleanor Carlyle, Kim Edmonds, Lyra Del Rosario, Karla Lingard, Mary Mangwende, Lucy Holt, Hamid Ahmod, Justine Korteweg, Tara Foley, Taja Barber, Stephanie Hepworth, Andrea Emslie-Henry, Niamh Caulfield-Lynch, Fiona Byrne, Daqi Deng, Bryan Williams, Michael Brown, Simon Caidan, Mike Gavrielides, James I. MacRae, Gavin Kelly, Kema Peat, Denise Kelly, Aida Murra, Kayleigh Kelly, Molly O'Flaherty, Sanjay Popat, Nadia Yousaf, Shaman Jhanji, Kate Tatham, David Cunningham, Nicholas Van As, Kate Young, Andrew J. S. Furness, Lisa Pickering, Rupert Beale, Charles Swanton, Sonia Gandhi, Steve Gamblin, David L. V. Bauer, George Kassiotis, Michael Howell, Susanna Walker, Emma Nicholson, James Larkin, Emma C. Wall, Samra Turajlic
Article
Oncology
Drew W. W. Rasco, Theresa Medina, Pippa Corrie, Anna C. C. Pavlick, Mark R. R. Middleton, Paul Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S. S. Agarwala, Adil I. I. Daud, Jiaheng Qiu, Viviana Bozon, Michelle Kneissl, Elly Barry, Anthony J. J. Olszanski
Summary: This study investigated the safety and antitumor activity of tovorafenib, a drug for treating solid tumors, and found that it has good antitumor activity in BRAF-mutated melanoma, particularly in patients who have not received RAF and MEK inhibitors. The study evaluated the safety and pharmacokinetic characteristics of two dosing schedules and identified the recommended dose as 200 mg or 600 mg administered once every other day or once weekly.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
James Larkin, Michele Del Vecchio, Mario Mandala, Helen Gogas, Ana M. Arance Fernandez, Stephane Dalle, Charles Lance Cowey, Michael Schenker, Jean -Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul D. Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey Weber
Summary: The study demonstrates that adjuvant nivolumab significantly improves recurrence-free survival and distant metastasis-free survival in high-risk melanoma patients who have undergone surgical resection, with sustained long-term benefits. Biomarkers such as tumor mutational burden, tumor PD-L1, intratumoral CD8+ T cells and IFNy-associated gene expression signature are associated with improved treatment outcomes, but their predictive value is limited.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Celeste Lebbe, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stephane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Michele Maio
Summary: The study aimed to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in patients with advanced melanoma. It found that the treatment was tolerable and had similar efficacy in all treated population with various subgroups, but reduced efficacy in patients with specific characteristics, indicating a need for novel treatment options.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Paolo Antonio Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion-Sileni, Brigitte Dreno, Stephane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Alberto Gomez-Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean-Jacques Grob
Summary: Preliminary research shows that nivolumab and relatlimab have better efficacy in treating advanced melanoma patients who have previously received anti-PD-(L)1 treatment. The RELATIVITY-047 trial demonstrated that nivolumab and relatlimab, compared to nivolumab alone, significantly improved progression-free survival in previously untreated advanced melanoma patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Andreas Michael Schmitt, James Larkin
Summary: Immune checkpoint inhibitors have had a significant impact on the prognosis of patients with various tumors, especially for melanoma patients who can achieve excellent outcomes with immunotherapy in both the adjuvant and advanced stages.
TRENDS IN UROLOGY & MENS HEALTH
(2023)
Article
Oncology
Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, Petr Arenberger, Lars Bastholt, Nicole Basset Seguin, Veronique Bataille, Lieve Brochez, Veronique del Marmol, Reinhard Dummer, Ana-Marie Forsea, Caroline Gaudy-Marqueste, Catherine A. Harwood, Axel Hauschild, Christoph Hoeller, Lidija Kandolf, Nicole W. J. Kellerners-Smeets, Aimilios Lallas, Ulrike Leiter, Josep Malvehy, Branka Marinovic, Zeljko Mijuskovic, David Moreno-Ramirez, Eduardo Nagore, Paul Nathan, Alexander J. Stratigos, Eggert Stockfleth, Luca Tagliaferri, Myrto Trakatelli, Ricardo Vieira, Iris Zalaudek, Claus Garbe, EADO, EDF, ESTRO, UEMS, V EAD
Summary: Basal cell carcinoma is the most common malignant tumor in white populations. This article provides updated recommendations on the diagnosis and treatment of BCC, including classification, surgical treatment, topical therapies, and the use of hedgehog inhibitors and immunotherapy. Regular skin examinations and long-term follow-up are also recommended for high-risk patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Simona Manacorda, Maria De Toro Carmena, Ciara Malone, Ha Mo Linh Le, Andrew J. S. Furness, James Larkin, Andreas M. Schmitt
Summary: This study investigated the efficacy of PD-1-directed antibody-based therapy in patients with symptomatic melanoma brain metastases (MBM) and concurrent treatment with corticosteroids. The findings showed that patients only derived modest benefit from the treatment, but those with disease response had the potential to derive long-term benefit, justifying the use of this therapy in this group in the absence of other more effective treatment options.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fabio Franke, Tudor E. Ciuleanu, Caio Pereira, Eva Munoz Couselo, Fernanda Bronzon Damian, Michael Schenker, Aldo Perfetti, Celeste Lebbe, Gaelle Quereux, Friedegund Meier, Brendan D. Curti, Carlos Rojas, Yull Arriaga, Haisu Yang, Ming Zhou, Shruthi Ravimohan, Paul Statkevich, Mary A. Tagliaferri, Nikhil I. Khushalani
Summary: Despite the efficacy of Bempegaldesleukin (BEMPEG) in the treatment of melanoma, the PIVOT IO 001 study did not meet its primary end points, with increased toxicity observed with the combination of BEMPEG plus NIVO.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Sarah Howlett, Thomas J. Carter, Heather M. Shaw, Paul D. Nathan
Summary: Tebentafusp is a novel immunotherapy agent that targets specific cells and has shown efficacy in treating advanced solid cancer and uveal melanoma. It is the first bispecific T-cell engager to demonstrate overall survival benefit and offers new possibilities for the management of advanced UM.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Surgery
Dale Vimalachandran, Robert P. Jones, Ed Dickson, Jaspreet Seehra, Austin Acheson, Ewen A. Griffiths, Sivesh Kamarajah, Elaine Leung, Andrew Torrance, Christian Ottensmeier, Andrew D. Beggs, Ellen Whiteside, Helen Sanna, Danielle Bury, Esther Youd, Gareth Leopold, Matthew Pugh, Sudha Sundar, Graham S. Taylor
BRITISH JOURNAL OF SURGERY
(2023)